Rein Therapeutics
RNTX
31 hedge funds and large institutions have $13.1M invested in Rein Therapeutics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 8 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
4.96% more ownership
Funds ownership: 21.25% → 26.21% (+5%)
3% less funds holding
Funds holding: 32 → 31 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
20% less capital invested
Capital invested by funds: $16.3M → $13.1M (-$3.22M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
+$2.9M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$300K |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$99.4K |
| 4 |
EWA
Exencial Wealth Advisors
Oklahoma City,
Oklahoma
|
+$92.5K |
| 5 |
BlackRock
New York
|
+$83.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$2.38M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.91M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.64M |
| 4 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
-$88.5K |
| 5 |
Renaissance Technologies
New York
|
-$46.6K |
RNTX Hedge Fund Activity: Q4 2024 in Review
31 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q4 2024, worth a combined $13.1M — down 20% from $16.3M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of RNTX and 7 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 8 added.
The largest buyer was Voss Capital, opening a new position worth an estimated $2.9M. The largest seller was University of Texas/Texas AM Investment Management Co (UTIMCO), cutting an estimated $2.38M.
- 31 institutional investors held Rein Therapeutics (RNTX) as of Q4 2024, down from 32 in Q3 2024.
- Funds reported $13.1M of Rein Therapeutics stock for Q4 2024, down 20% quarter-over-quarter.
- 7 funds opened new Rein Therapeutics positions in Q4 2024 and 8 closed out, a net change of -1 holder.
- The largest Rein Therapeutics buyer in Q4 2024 was Voss Capital, an estimated $2.9M added.
- The largest Rein Therapeutics seller in Q4 2024 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $2.38M sold.
Based on aggregated 13F filings for Q4 2024.